![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Active Filter(s):
Details:
The financing will support Magnet's approach to the discovery and development of TrueGlues™, compounds inducing cooperative protein-protein interactions and will advance its portfolio spanning several indications, including oncology, cardiovascular, and immune disorders.
Lead Product(s): Undisclosed
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Small molecule
Partner/Sponsor/Collaborator: Newpath Partners
Deal Size: $50.0 million Upfront Cash: Undisclosed
Deal Type: Series A Financing September 19, 2023